Clinical Trial: An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07680257) titled 'An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors' on June 22.

Brief Summary: An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.

Study Start Date: Dec. 27, 2025

Study Type: INTERVENTIONAL

Condition: CLDN18.2 Positive Solid Tumors

Intervention: BIOLOGICAL: SUV2208A cell injection

SUV2208A, DL1, 2 times, Day 0 and Day 28, IV

BIOLOGICAL: SUV2208A

SUV2208A, ...